Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) -- The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials and Trends, 2021" report has been added to ResearchAndMarkets.com's offering.
CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."
T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, an exponential increase in clinical trial activity, proliferative M&A activity, and lucrative IPOs have created a robust CAR-T cell market. This billion dollar market would not have been possible without the remarkable efficacy of Kymriah, Yescarta, and Tecartus in treating several types of blood cancers.
Today, the CAR-T cell therapy industry is witnessing:
Landmark approvals of CAR-T cell therapies by regulatory bodies worldwide
Lucrative acquisitions within the CAR-T industry
Large IPOs within the industry
An increasingly competitive IP environment
Unprecedented investment flowing into CAR-T cell research
This global strategic report reveals:
Market size determinations with segmentation and forecasts through 2027
Approved CAR-T products by indication and region
Clinical trial activity by type, region, phase, and sponsor
CAR-T industry M&A transactions and IPOs
Strategic partnerships and commercialization agreements
Industry trends and future directions
Competitors composing the global marketplace
This 232-page global strategic report will position you to:
Capitalize on emerging trends
Improve internal decision-making
Reduce company risk
Approach outside partners and investors
Out compete your competition
Implement an informed and advantageous business strategy in 2021
Key Topics Covered:
1. Report Overview
2. Chimeric Antigen Receptor-T (Car-T) Cell Therapy: A Brief Overview
3. History of CAR-T Cell Therapy
3.1 Current Status of CAR-T Therapy Products
3.2 Prospective CAR-T Product Candidates
3.3 Transformative Potential of CAR-T Therapy
3.4 Small Patient Population & Huge Clinical Trial Landscape
4. Manufacture of CAR-T Cells
4.1 Automation in CAR-T Manufacturing
4.2 Operating Expenses in Autologous CAR-T Manufacturing
4.3 Operating Expenses in Allogeneic CAR-T Manufacturing
5. CAR-T Target Antigens: A Brief Overview
5.1 CAR-T Target Antigens on Hematological Cancers
5.2 CAR-T Target Antigens on Solid Tumors
5.3 Common Antigens Targeted by CAR-T Cells
5.3.1 Cluster of Differentiation 19 (CD19)
5.3.3 B-Cell Maturation Agent (BCMA)
5.3.5 Glypican-3 (GPC3)
5.3.6 Cluster Differentiation-22 (CD22)
6. CAR-T Patent Landscape
6.1 Geographical Origin of CAR-T Patent Applications
6.2 Top Ten CAR-T Patent Jurisdictions
6.3 Affiliations of CAR-T Cell Patent Applicants
6.3.1 Top 20 Companies in CAR-T Patent Landscape
6.3.2 TOP 20 Research Centers in CAR-T Patent Landscape
6.3.3 Top 20 CAR-T Cell Inventors
6.3.4 Top Five CAR-T Patents with Most Family Members
6.3.5 Top Five CAR-T Patents with Most Inventors in Co-Authorship
6.3.6 Top Five Patents with Most Co-Applicants
6.3.7 Top Five CAR-T Patents with Most Citations Received
7. Global CAR-T Clinical Trials: An Overview
7.1 CAR-T Targeted Biomarkers in Clinical Trials
7.2 CAR-T Targeted Indications in the U.S. Clinical Trials
7.3 Indications Addressed by CAR-T Clinical Trials in China
7.4 Percent Share of Indications Addressed by the Ongoing CAR-T Clinical Trials
7.5 Phase of CAR-T Clinical Trials
7.6 CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
7.7 CAR-T Clinical Trial Sponsor Companies and Institutions in China
7.8 CAR-T Clinical Trial Sponsor Companies and Institutions in other Countries
7.9 Ongoing Clinical Trials with Improved CAR-T Constructs
7.10 Geographic Distribution of CAR-T Clinical Trials
7.11 Distribution of CAR-T Clinical Trials by Type of CAR Generations
7.12 Distribution of CAR-T Clinical Trials by Type of ScFv Used
7.13 Distribution of CAR-T Clinical Trials by Type of Vectors Used
8. Published Scientific Papers & NIH Grants
8.1 Number of Published Papers
8.2 NIH Funding for CAR-T Research
9. Deals in CAR-T Therapy Space
9.1 Most Recent CAR-T Deals
9.1.1 Gilead Sciences/Tango Therapeutics
9.1.4 Juno/Oxford Biomedica
9.1.6 Applied DNA Sciences, Inc.
9.1.8 Cell Therapies, Pvt. Ltd
9.1.11 Carisma Therapeutics, Inc./NYU Langone Health
10. Marketed CAR-T Products
10.1 Kymriah (Tisagenlecleucel)
10.2 Yescarta (Axicabtagene ciloleucel)
10.3 Tecartus (Brexucabtagene autoleucel)
10.4 Other Promising CAR-T Product Candidates
11. Reimbursement for Car-T Therapies
11.1 Hospital Reimbursement in the U.S. for CAR-T Therapy
11.2 Outcomes-Based Reimbursement for CAR-T Therapies in EU5 Countries
12. Blood Cancers: An Overview
12.3 Multiple Myeloma (MM)
12.4 Treatment Options for Blood Cancers
12.5 The Staggering Cost of Cancer Therapy
13. Market Analysis
13.1 Global Market for CAR-T Cell Therapy by Product
13.2 Global CAR-T Market by Geography
13.3 Global Market for CAR-T Therapy by Indication
13.4 Companies at the Forefront of CAR-T Market
13.5 Barriers and Strategies for Success in CAR-T 2.0 Market Place
13.5.1 Barriers to CAR-T 2.0 Commercial Success
22.214.171.124 Capacity constraints
126.96.36.199 Competition among Manufacturers
188.8.131.52 Competition from other Treatments
13.5.2 Market Development Strategies for CAR-T 2.0
184.108.40.206 Effective Physician Education
220.127.116.11 Logistical Excellence
18.104.22.168 Evidence Generation
14. Company Profiles
14.1 Aleta BioTherapeutics
14.1.1 Atela's Pipeline
14.2 Allogene Therapeutics
14.2.1 AlloCAR-T Therapy
14.3 Anixa Biosciences, Inc.
14.4 Attars Biotherapeutics
14.4.2 Next-Generation CAR-T
14.5 Autolus Therapeutics, plc
14.6 Bellicum Pharmaceuticals, Inc.
14.6.1 GoCAR Technology
14.6.2 Bellicum's Pipeline
14.7.3 Engineered Cell Therapies
14.7.4 CAR-T Programs
14.8 bluebird bio
14.8.1 CAR-T Collaborations
22.214.171.124 Collaboration with Celgene
126.96.36.199 Collaboration with Inhibrx
188.8.131.52 Collaboration with TC BioPharm
14.9 Carina Biotech
14.9.1 New CAR-T Cells
14.9.2 CAR-T Access Technologies
184.108.40.206 Chemokine Receptor Mediation
220.127.116.11 Gel Formulation to Deliver CAR-T Cells
14.10 CARsgen Therapeutics
14.11 Cartesian Therapeutics, Inc.
14.11.1 Cartesian's Approach
14.13 Celgene Corporation
14.13.1 Lisocabtagene maraleucel (liso-cel)
14.14.1 Universal Chimeric Antigen Receptor T-Cells (UCARTs)
14.15 Celularity, Inc.
14.15.1 P CAR-T
14.16 Celyad Oncology
14.16.1 TIM Technology
14.16.2 shRNA Technology
14.17 Creative Biolabs
14.17.1 CAR Construction and Production Platform
14.18 CRISPR Therapeutics
14.18.1 CRISPR/Cas9 Immuno-Oncology Cell Therapy
14.19 Cytovia Therapeutics
14.20 DiaCarta, Inc.
14.20.1 Personalized CAR-T Immunotherapy Platform
14.21 Empirica Therapeutics
14.22 Eureka Therapeutics, Inc.
14.23 EXUMA Biotech Corp.
14.23.1 Logic Gate CAR-T Technology
14.23.2 Same-Day CAR-T Therapy
14.24 Fate Therapeutics, Inc.
14.25 Formula Pharmaceuticals, Inc.
14.26 Gilead Sciences, Inc.
14.26.1 TECARTUS (Brexucabtagene autoleucel)
14.26.2 Yescarta (Axicabtagene ciloleucel)
14.26.3 Cell Therapy
14.27 Gracell Biotechnologies
14.27.1 Dual CAR
14.28 iCell Gene Therapeutics
14.28.1 iCell Platforms
18.104.22.168 Non Gene Edited Universal CARs
22.214.171.124 T-Cell Targeted CARs
126.96.36.199 Compound CARs
14.29 Janssen Biotech, Inc.
14.30 Juno Therapeutics
14.31 JW Therapeutics, Co., Ltd.
14.31.1 Relmacabtagene autoleucel (Relma-cel)
14.32 Kite Pharma, Inc.
14.32.1 Kite's Technologies (CAR-T & TCR)
14.32.2 Kite's Therapies
188.8.131.52 Yescarta (Axicabtagene ciloleucel)
184.108.40.206 Tecartus (Brexucabtagene autoleucel)
14.33 MaxCyte, Inc.
14.33.1 CARMA Cell Therapies
14.33.2 Flow Electroporation Technology
14.34 Minerva Biotechnologies Corporation
4.35 Mustang Bio, Inc.
14.36 Nanjing Legend Biotechnology Co., Ltd.
14.37 Noile-Immune Biotech
14.38 Novartis International, AG
14.38.1 Kymriah (Tisagenlecleucel)
14.39 Oxford Biomedica plc
14.40 PeproMene Bio, Inc.
14.40.1 BAFF-R CAR-T Cells
14.41 Poseida Therapeutics, Inc.
14.41.1 PiggyBac DNA Modification System
14.41.2 Autologous & Allogeneic Programs
14.42 Precigen, Inc.
14.43 Precision Biosciences
14.44 Prescient Therapeutics
14.44.1 OmniCAR Technology
14.45 ProMab Biotechnologies, Inc.
14.45.1 Custom CAR-T Cell Development
14.47 Sorrento Therapeutics, Inc.
14.48 TC Biopharm
14.48.1 Co-Stim CAR-T
14.50 Tessa Therapeutics, Pvt. Ltd.
14.50.1 CD30 CAR-T Cells
14.50.2 Allogeneic CD30-CAR EBVSTs
14.51 Tmunity Therapeutics, Inc.
14.53 Xyphos Biosciences, Inc.
14.53.1 Xyphos' Strategy
14.54 Ziopharm Oncology, Inc.
14.54.1 Non-Viral CAR-T Therapy
For more information about this report visit https://www.researchandmarkets.com/r/w3u0qi
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900